SAN FRANCISCO, June 3 CA-VIA-Pharma-Needham
SAN FRANCISCO, June 3 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals
(Nasdaq: VIAP), a biotechnology company focused on the development of
compounds for the treatment of cardiovascular disease, announced today that
Lawrence K. Cohen, PhD, president and chief executive officer of VIA, and
James G. Stewart, senior vice president and chief financial officer, will
present a company update at the Seventh Annual Needham & Company Biotechnology
and Medical Technology Conference on Wednesday, June 11, 2008 at 2 p.m. ET at
the New York Palace Hotel in New York City.
Interested parties may access a live audio webcast of the presentation
from the investor section of the VIA website,
http://www.viapharmaceuticals.com. A replay of the presentation will be
archived on the VIA website for at least one week following the presentation.
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the
development of compounds for the treatment of cardiovascular disease. VIA is
building a pipeline of small-molecule drugs that target a significant unmet
medical need: reducing inflammation in the blood vessel wall, which is an
underlying cause of atherosclerosis and its complications, including heart
attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple
Phase 2 clinical studies in patients with cardiovascular disease. For more
information, visit: http://www.viapharmaceuticals.com.
SOURCE VIA Pharmaceuticals, Inc.
